Human epidermal growth factor receptor 2 (HER2) amplified carcinomas, constituting 10 to 30% of primary tumours and about 30% of metastases, are aggressive but can be treated with monoclonal antibodies (Trastuzumab) [4, 10, 11]. This evidence concerns the gene ERBB2 and carcinoma.